AI in multiple myeloma: Recent findings and opportunities

Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM patients

Daratumumab-based maintenance regimens show favourable responses in transplant-eligible NDMM

Optimising benefit-risk and minimising impact on quality of life with BCMA-targeting agents in an outpatient setting

Understanding the remaining unmet needs in a post ASCT NDMM setting

Approaches to risk stratification in high risk myeloma

Use of bispecifics and CAR T cells in South America

Tailored to fit: New approaches in transplant-ineligible NDMM

Advancements in minimal residual disease detection in myeloma

Novel biomarkers in myeloma: CTCs and cfDNA

New classification for identifying HR myeloma based on cytogenetic abnormalities

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Use of bispecifics and CAR T cells in South America

Revolutionising myeloma treatment through immune profiling

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Guiding transplant decisions in multiple myeloma with MRD

Revolutionising multiple myeloma treatment with CAR T-Cell therapies

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies